| __timestamp | Arrowhead Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 189101000 |
| Thursday, January 1, 2015 | 57410147 | 96351000 |
| Friday, January 1, 2016 | 41454452 | 95967000 |
| Sunday, January 1, 2017 | 31690298 | 112171000 |
| Monday, January 1, 2018 | 52968505 | 182257000 |
| Tuesday, January 1, 2019 | 81048686 | 336964000 |
| Wednesday, January 1, 2020 | 128874979 | 547851000 |
| Friday, January 1, 2021 | 206342000 | 693716000 |
| Saturday, January 1, 2022 | 297307000 | 891813000 |
| Sunday, January 1, 2023 | 353188000 | 1044071000 |
| Monday, January 1, 2024 | 505870000 | 910408000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated significant growth in their R&D investments.
Exelixis, Inc. has shown a remarkable increase, with R&D expenses growing by over 450% from 2014 to 2023. This surge underscores their dedication to advancing cancer therapies. Meanwhile, Arrowhead Pharmaceuticals, Inc. has also ramped up its R&D spending, increasing by more than 2,000% during the same period, reflecting their focus on RNA interference technology.
The data reveals a consistent upward trend in R&D investments, highlighting the strategic importance of innovation in the biotech sector. However, 2024 data for Exelixis is missing, leaving room for speculation on their future trajectory.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Arrowhead Pharmaceuticals, Inc.
AstraZeneca PLC or Exelixis, Inc.: Who Invests More in Innovation?
R&D Insights: How Takeda Pharmaceutical Company Limited and Exelixis, Inc. Allocate Funds
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
United Therapeutics Corporation vs Exelixis, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.
Summit Therapeutics Inc. vs Exelixis, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: BioMarin Pharmaceutical Inc. and Exelixis, Inc.
Research and Development Investment: Exelixis, Inc. vs Alpine Immune Sciences, Inc.
Exelixis, Inc. or Soleno Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Bausch Health Companies Inc. and Arrowhead Pharmaceuticals, Inc.